Prediabetes does not cause small fiber neuropathy (P5.118)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To evaluate the association between glycemic status and small fiber neuropathy (SFN)
Background: The association between prediabetes (PD) and SFN is controversial.
Design/Methods: A cohort of patients with symptoms consistent with SFN, attending the neuromuscular clinic at the University of Nebraska Medical Center was reviewed. All patients had normal electrophysiologic studies and underwent tests to assess small nerve fibers. SFN was diagnosed based on at least 2 abnormal tests of QSART, QST or skin biopsy. PD is defined by fasting plasma glucose (FPG) of 100–125 mg/dL, 2-hour glucose of 140–199 mg/dL or HgA1C of 5.7–6.4%. Diabetes mellitus (DM) is defined by FPG ≥ 126 mg/dL, 2-hour glucose of ≥ 200 mg/dL or HgA1C ≥6.5%. Patients with other causes of SFN were excluded.
Results: 199 patients were reviewed. 82 patients were excluded due to the presence of other causes of SFN. Among 117 patients included, 10 had DM, 37 had PD, 54 had normoglycemia (NG) and 16 had unknown glycemic status. There was no difference between age, gender and duration of neuropathic symptoms between DM, PD and NG. There was no significant difference in intraepidermal fiber density (IENFD) at the ankle between PD and NG. The rate of skin biopsy abnormality and SFN was not higher in PD compared to NG. In contrast, ankle IENFD was lower in DM compared to PD or NG, and the rate of skin biopsy abnormality and SFN was higher in DM than in PD and NG. Linear regression analysis showed an association between HgA1C and IENFD if DM patients were included but not in PD and NG alone.
Conclusions: We found no evidence of a higher prevalence of SFN or abnormality of IENFD in PD relative to NG in patients presenting with distal sensory symptoms. PD does not appear alone to cause SFN.
Disclosure: Dr. Thaisetthawatkul has nothing to disclose. Dr. Fernandes has nothing to disclose. Dr. Herrmann has received personal compensation for activities with Medpace as Clinical Trial Adjudication.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.